AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

ConferenceABBV-1480telisotuzumab adizutecanABBV-706Positive

AI Analysis

Summary

AbbVie will present clinical data from its lung cancer pipeline at WCLC 2026, including data from ABBV-1480 (RC148) bispecific antibody in frontline NSCLC and updates on Temab-A and ABBV-706 programs.

Importance:5/10

Sentiment:

0.30

lung cancerNSCLCPD-1/VEGF bispecificpipeline updateWCLC 2026oral presentation

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on August 21, 2026 11:45 AM

Read Original